858 Therapeutics

858 Therapeutics is a life sciences company in San Diego, United States, founded in 2019. It has 2 recorded funding rounds, most recently a Series B in September 2024.

8five8 Therapeutics | Developing a new class of targeted therapy to improve the lives of cancer patients

Employees
11–50
Founded
2019
Business Model
B2B
Last Round
Series BSep 2024
Rounds
2

Indexed holds 2 funding rounds and 4 investors for this company. The full record is or through the API.

About

858 Therapeutics is a clinical-stage biotechnology company developing first-in-class and best-in-class therapies designed to target tumor dependencies in DNA damage response (DDR) pathways. Its lead program, ETX-19477, is an oral, potent, and selective PARG inhibitor being investigated in a Phase 1/2 clinical study in patients with advanced solid tumors. PARG inhibition has the potential to address key mechanisms of resistance in solid tumors and expand treatment options for patients with cancer.

Summary

It lists 11–50 employees. Its most recent funding was a Series B round in Sep 2024. Investors include Avidity Partners, Versant Ventures and Insight Partners.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Series BSeries BSep 2024

Sign up to see all 2 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

858 Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/858-therapeutics"><img src="https://indexed.vc/api/badge/company/858-therapeutics" alt="858 Therapeutics on Indexed.vc" width="260" height="76" /></a>